Revised Medicare Fee Schedule Will Impact Endocrinologists

On December 1, 2020, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule (MPFS) final rule for CY 2021.

This rule updates payment policies and payment rates for Part B services furnished under the MPFS, as well as makes changes to the Quality Payment Program.

As a result of changes included in the rule, endocrinologists are expected to see a 13% increase in Medicare reimbursement while other specialties faced significant cuts. However, in an unusual move, Congress revised provisions of the Medicare regulation in its final year-end legislation to mitigate the cuts for some specialties.

Congress revised provisions of the Medicare regulation in its final year-end legislation to mitigate the cuts for some specialties.

Consequently, funding for the add-on complexity code for office E&M that would have been applied to essentially all endocrinology visits was removed and will reduce the amount of the previously predicted increase in total Medicare reimbursements for endocrinologists.

The Society has provided additional information on this reimbursement change at: www.endocrine.org/improving-practice/macra.

You may also like

  • Endocrine Society Participates in European Union Activity to Advise on Implementation of its Chemical Strategy

    The Endocrine Society achieved a major victory in the new European Union (EU) Chemicals Strategy for Sustainability (CSS) by including several priority actions on endocrine-disrupting chemicals (EDCs) within the strategy. The CSS commits the EU towards a series of actions to better protect citizens and the environment and promote innovation in safe and sustainable chemicals….

  • Endocrine Society Leads Efforts to Lower Cost of Prescription Drugs

    The Endocrine Society continues to lead advocacy efforts focused on lowering the cost of diabetes medication. The Society has weighed in on recent congressional and administration activity regarding legislation and regulations aimed at lowering the price of prescription drugs.    In May, the House Energy & Commerce Health subcommittee conducted a hearing on legislation to lower the cost of prescription drugs. The Endocrine Society submitted a statement to the subcommittee calling on Congress to…

Find more in